PLASMATECH BIOPHARMACEUTICALS INC 4
4 · PLASMATECH BIOPHARMACEUTICALS INC · Filed Dec 29, 2014
Insider Transaction Report
Form 4
Jeffrey B Davis
DirectorChief Executive Officer
Transactions
- Other
Common Stock
2014-12-24$4.00/sh+594,801$2,379,204→ 662,659 total(indirect: By LLC) - Conversion
Series A Cumulative Convertible Preferred Stock
2014-12-24$4.00/sh−237.921$952→ 0 total(indirect: By LLC)Exercise: $4.00From: 2014-12-24Exp: 2014-12-24→ Common Stock (594,801 underlying) - Purchase
Common Stock
2014-12-24$4.00/sh+62,500$250,000→ 67,858 total(indirect: By LLC) - Other
Common Stock
2014-12-24$4.00/sh+300,852$1,203,408→ 963,511 total(indirect: By LLC) - Purchase
Common Stock Purchase Warrants
2014-12-24$0.01/sh+62,500$625→ 62,500 total(indirect: By LLC)Exercise: $5.00From: 2014-12-24Exp: 2019-12-24→ Common Stock (62,500 underlying)
Footnotes (3)
- [F1]Jeffrey B. Davis is the managing member of Lake End Capital LLC
- [F2]Series A Cumulative Convertible Preferred Stock was converted by the Company into common stock on 12/24/2014.
- [F3]Series A Preferred Stock dividends due and interest due on dividends and liquidated damages were converted into common stock by the company on 12/24/2014.